勒马回胶囊联合抗菌药物治疗支气管扩张效果及对症候改善、血清炎症因子的影响

The effects of Lemahui capsule combined antimicrobial treatment in treating bronchiectasis and its effect on symptoms improvement and serum inflammatory factors

目的:研究勒马回胶囊联合抗菌药物治疗支气管扩张效果及对证候改善、血清炎症因子的影响。方法:将我院2016年2月—2017年2月收治的180例支气管扩张患者采用随机数字表法均分为观察组(勒马回胶囊+抗菌药物,n=90)与对照组(抗菌药物,n=90),观察两组治疗后证候改善情况、血清炎症因子水平与治疗总有效率。结果:治疗后,两组证候得分均较治疗前显著改善,且观察组改善幅度更大(P<0.05);治疗后,两组血清ESR、PCT、hs-CRP水平均较显著下降,且观察组各物质下降幅度均更大(P<0.05);观察组、对照组治疗总有效率分别为91.11%和73.33%,(P<0.05)。结论:勒马回胶囊联合抗菌药物可有效改善支气管扩张患者临床症状,显著降低患者血清炎症水平。

Objective： To study the effect of Lemahui capsule（勒马回胶囊） combined antimicrobial treatment in treating bronchiectasis and its effect on symptoms improvement and serum inflammatory factors. Methods： 180 patients with bronchiectasis treated in our hospital from February 2016 to February 2017 were selected and divided into the observation group （ Lemahui capsule（勒马回胶囊） combined antimicrobial treatment, n=90） and the control group （antibacterial drugs, n=90） by using random number table method, the symptoms, the serum levels of inflammatory factors and treatment efficiency of two groups after treatment were observed. Results： After treatment, the scores of both groups were significantly improved compared with those before treatment, and the observation group improved more significantly （P〈0.05）. After treatment, the levels of ESR, PCT and hs-crp in both groups decreased significantly, and the decreasing of all substances in the observation group was more significant （P〈0.05）. The effective rate of treatment in observation group and control group was 91.11% and 73.33% respectively （P〈0.05）. Conclusion： Lemahui capsule（勒马回胶囊） combined antimicrobial treatment could effectively relieve the clinical symptoms of patients with bronchiectasis, and significantly reduce the level of serum inflammation in patients.